Immunomagnetic Separation of CD34<sup>+</sup>Cells from Human Bone Marrow, Cord Blood, and Mobilized Peripheral Blood

Ishizawa, Lori; Hangoc, Giao; Ven, Carmella van de; Cairo, Mitchell S.; Burgess, Julie; Mansour, Virginia H.; Gee, Adrian P.; Hardwick, Alan; Traycoff, Christie M.; Srour, Edward F.; Hoffman, Ronald; Law, Ping

doi:10.1089/scd.1.1993.2.333

Cited by 24 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34+ cells were purified by an immunomagnetic method (Isolex system, Baxter, Santa Ana, Calif., USA), as described elsewhere [9]. This method does not affect the surface phenotype or the potential of these CD34+ cells for engraftment [10]. The PBSCs obtained from the two patients in complete remission were washed twice with a working solution (RPMI-1640 medium, Sigma, containing 0.4% sodium citrate and 0.9% human serum albumin) by centrifugation at 200 g for 10 min at room temperature to remove platelets.…”

Section: Methodsmentioning

confidence: 99%

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Takekawa¹,

Yamane²,

Hino³

et al. 1998

Acta Haematol

View full text Add to dashboard Cite

We evaluated the usefulness of an automated hematology analyzer (SE-9000) for the identification and counting of peripheral blood stem cells (PBSCs). The samples tested were from 14 patients with hematological malignancies. Peripheral blood samples were collected from the subjects before and after a course of chemotherapy. From the leukapheresis sample, CD34+ cells, assumed to be hematopoietic stem cells, were obtained with an immunomagnetic cell separator. The CD34+ cells obtained accumulated in the gate corresponding to low recurrent frequencies of the automated hematology analyzer. This gate shows results of the ‘immature information’ (IMI) channel. Software for detection of only the cells that accumulated in this gate was therefore developed. With this trial program, the regression coefficient between the percentage of leukocytes from the blood samples that were CD34+ and the percentage of such leukocytes that appeared on the IMI channel was 0.79. With this analyzer, the number of PBSC could be counted in about 80 s. The identification and counting of cells picked up by the IMI channel should be clinically useful for the monitoring of changes in PBSC after chemotherapy for mobilization.

show abstract

Section: Methodsmentioning

confidence: 99%

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Takekawa¹,

Yamane²,

Hino³

et al. 1998

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…The CD34-positive selection using the Isolex 50 magnetic cell separation system (Baxter Immunotherapy Division, Santa Ana, CA, USA) from haploidentical father (cases 7, 10) and PBSC collection from HLA-match sibling was carried out as previously described. 18,22 In none of the cases were specific T cell depletion procedures employed. With bone marrow cells, the mononuclear cell number infused was a median 4.2 × 10 8 /kg (range 1.0 × 10 8 /kg to 4.8 x 10 8 /kg) and with the two cord blood infusions 6.8-10 × 10 7 /kg (as CFU-GM, 3.0-3.4 × 10 4 /kg) were given.…”

Section: Stem Cell Transplantationmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan

Imashuku

Hibi

Todo

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Seventeen cases (age at onset, 1 month to 18 years; M/F, 9/8) of hemophagocytic syndrome which received allogeneic hematopoietic stem cell transplantation (SCT) in Japan during the period 1988-1998 are reported. The patients consisted of six familial inheritance-proven erythrophagocytic lymphohistiocytosis (FEL), five familial inheritance-unknown and infective agentsunknown HLH (of which two were highly likely to have been FEL with characteristic CNS signs), and six aggressive Epstein-Barr virus (EBV)-related HLH (of which two were natural killer cell-type large granular leukemia/lymphoma-associated hemophagocytic syndrome, EBV-NK-LGLL-HPS). All cases were treated intensively with immuno-chemotherapy, or with chemotherapy before SCT. As sources of SCT, 12 cases received bone marrow cells (sibling six, father one, URD five), two cord blood, two purified CD34-positive cells, and one PBSC. SCTs were successful in all 17 cases, apart from one receiving CD34-positive SCT. Following SCT, four patients relapsed and five died with a median follow-up of 23 months. Among the relapsed cases, the two EBV-NK-LGLL-HPS previously published as successfully transplanted were included. Among the fatal cases, three patients died from relapsed active disease and the remaining two from fatal post-SCT EBV-positive T cell lymphoma and extensive chronic GVHD, respectively. As of the end of September 1998, 10 patients are alive without disease for 3.5 months to 147 months, while two post-SCT patients are still having therapy for residual/recurrent disease. The KaplanMeier analysis showed a 2-year event-free survival after SCT as 54.0 ؎ 13.0%.

show abstract

“…15,16 The two CD34 + stem cell selection systems adopted in clinical use are based on either biotin-avidin immunoadsorption (Ceprate SC) 17 or indirect immunomagnetic beads (Isolex 300). 18 Most clinical trials of TCD in allo-PBT by means of CD34 + positive selection (allo-PBT/CD34 + ) have been accomplished with the former method, [3][4][5][6][7] and few data about the use of immunomagnetic 520 CML = chronic myeloid leukemia; ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; CLL = chronic lymphocytic leukemia; NHL = non-Hodgkin lymphoma; MM = multiple myeloma; RAEBt = refractory anemia with excess of blasts in transformation; a = first complete remission or first chronic phase in CML; b = disease chemoresistant or in relapse; Cy = cyclophosphamide (120 mg/kg); TBI = total body irradiation; Bu = busulfan (16 mg/kg); CsA = cyclosporin A; PDN = methylprednisolone; c 3 mg/kg ev from day Ϫ1, maintaining blood levels of 250-400 ng/ml; d 0.5 mg/kg day +7 to +14, 1 mg/kg day +15 to +28, tapering the doses afterwards; e days +1, +3, +6.…”

mentioning

confidence: 99%

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique

Urbano-Ispizúa¹,

Solano²,

Brunet³

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The objective of this study was to analyze CD34 + cell recovery and T cell depletion (TCD) achieved in CD34 + cell grafts using either immunoadsorption or immunomagnetic methods applied to leukapheresis products from healthy donors. We also wanted to determine the kinetics of engraftment and incidence and severity of graft-versus-host disease (GVHD) after allogeneic transplantation of selected CD34 + cells. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were selected using immunoadsorption (Ceprate SC) (n = 38) or immunomagnetic (Isolex 300) (n = 24) methods. Sixty-two patients, with a median age of 42 years (range 17-60) diagnosed with hematological malignancies were conditioned with either cyclophosphamide and total body irradiation (n = 43) or busulphan and cyclophosphamide (n = 19). GVHD prophylaxis consisted of cyclosporin A (CsA) and prednisone (n = 48), CsA alone (n = 11) and CsA and methotrexate (n = 3). The median yield and purity of CD34 + cells after the procedure was 65 and 66% with immunoadsorption, and 48 and 86% with immunomagnetic method, respectively. The median number (range) of CD34 + cells infused into the patients was 3.5 ؋ 10 6 /kg (1-9.6). The median number (range) of CD3 + cells administered was 0.4 ؋ 10 6 /kg (0.01-2) using immunoadsorption and 0.14 ؋ 10 6 /kg (0.03-2.5) using immunomagnetic methods. Neutrophil recovery Ͼ500 and Ͼ1000/ l was achieved at a median (range) of 13 days (8-22) and 14 days (9-31), respectively. Platelets recovered to Ͼ20 000 and Ͼ50 000/ l at a median (range) of 13 days (0-128) and 18 days (0-180), respectively. Two patients developed graft failure. Acute GVHD in patients at risk was clinical grade 0 (n = 43), I (n = 8), II (n = 4) and III (n = 1). No patient developed acute GVHD grade IV. Chronic GVHD was limited in two cases and extensive in four cases. The actuarial probability of acute GVHD II-IV was 10% (95% CI, 1-19%), and of extensive chronic GVHD was 12% (95% CI, 11-13%). The cumulative incidence of transplantrelated mortality was 12.6%, and this figure was 9% at 6 months. In conclusion, with the immunomagnetic procedure, a lower recovery and higher purity of CD34 + cells, and stronger TCD is obtained as compared to immunoadsorption (P = 0.008, P Ͻ 0.0001 and P = 0.0002, respectively). Our results also indicate that allogeneic transplantation of selected CD34 + cells is associated with a very rapid engraftment and with a low incidence of severe GVHD.

show abstract

Immunomagnetic Separation of CD34⁺Cells from Human Bone Marrow, Cord Blood, and Mobilized Peripheral Blood

Cited by 24 publications

References 7 publications

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique

Contact Info

Product

Resources

About

Immunomagnetic Separation of CD34+Cells from Human Bone Marrow, Cord Blood, and Mobilized Peripheral Blood

Cited by 24 publications

References 7 publications

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Determination of Hematopoietic Stem Cells in Peripheral Blood by an Automated Hematology Analyzer (SE-9000)

Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique

Contact Info

Product

Resources

About

Immunomagnetic Separation of CD34⁺Cells from Human Bone Marrow, Cord Blood, and Mobilized Peripheral Blood